Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-06

Study Completion Date

2034-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT06599411

Atopic Dermatitis Psoriasis Hidradenitis Suppurativa +7 more

NOT_YET_RECRUITING

Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.

NCT03559465

Scleroderma, Systemic

COMPLETED NA

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

NCT03976622

Vitiligo Psoriasis Alopecia Areata +1 more

UNKNOWN

Coagulopathy of Immunodermatologic Diseases

NCT06037187

Autoimmune Bullous Dermatosis

RECRUITING

Implementation of a Biological Sample Collection in Systemic Sclerosis Patients

NCT04986514

Systemic Sclerosis

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Autoimmune diseases include around a hundred different clinical entities which are for the most part rare pathologies but which, in combination, concern 5-8% of the adult population with a strong female predominance (FAI²R: the disease chain rare autoimmune and auto-inflammatory drugs, fai2r.org). The common denominator of all these diseases is based on the breakdown of self-tolerance which is the origin of self-reactivity and whose physiopathological mechanisms are still not fully understood, which generates numerous cross-sectional or fundamental studies. In addition to this complexity, there are significant inter-individual variabilities which lead to the definition of subgroups of patients on the basis of the clinical-biological profile and / or the response to treatments. Consequently, and in view of the need to establish the diagnosis early and then to propose the best treatment in the perspective of an individualized medicine, the clinical, biological and genetic characteristics of these subgroups of patients must be explored in order to improve diagnostic and therapeutic capacities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Bullous Dermatosis Dysimmune Dermatological Diseases Auto-inflammatory Dermatological Diseases Skin Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients suffering from autoimmune, dysimmune or auto-inflammatory dermatological disease

Biological samples will be collected in the normal diagnosis and follow-up process

Blood sampling

Intervention Type BIOLOGICAL

Blood will be taken in larger quantity

Remainders of samples taken as part of the treatment

Intervention Type BIOLOGICAL

blood, CSF, saliva, stools, urine, other biological fluids and tissue biopsies, hair follicles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling

Blood will be taken in larger quantity

Intervention Type BIOLOGICAL

Remainders of samples taken as part of the treatment

blood, CSF, saliva, stools, urine, other biological fluids and tissue biopsies, hair follicles

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Skin damage of documented or probable autoimmune, dysimmune or autoinflammatory origin.

The patients included may be adults or children, and will be:

* Patients with autoimmune bullous dermatoses (pemphigus, pemphigoid and others),
* Patients with systemic autoimmune diseases associated with skin damage (lupus, scleroderma, dermatomyositis for example),
* Patients with cutaneous lupus
* Patients with dysimmune skin diseases (psoriasis, eczema)
* Patients with immuno-induced dermatological disorders or drug dermatitis
* Patients receiving, or likely to receive, new, innovative therapies (new molecule on the market, checkpoint inhibitors, gene therapy, cell therapy, etc.).

Patients with dermatological damage whose autoimmune, dysimmune or auto-inflammatory origin is suspected